Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:HRMYNASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$21.64+0.9%$23.73$14.97▼$26.58$2.62B0.661.12 million shs687,432 shsHRMYHarmony Biosciences$32.09-0.1%$33.20$26.47▼$41.61$1.85B0.83630,594 shs287,680 shsNVAXNovavax$6.80+0.5%$6.76$5.01▼$17.81$1.10B2.696.30 million shs2.29 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.89%-1.14%-13.13%-6.20%+41.35%HRMYHarmony Biosciences-0.06%+0.72%-9.12%+9.67%+3.88%NVAXNovavax+0.52%+4.54%-6.40%+8.89%-45.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.9263 of 5 stars3.61.00.03.93.33.33.8HRMYHarmony Biosciences4.795 of 5 stars4.61.00.00.02.83.34.4NVAXNovavax4.4897 of 5 stars3.12.00.04.71.10.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.25Buy$32.8351.73% UpsideHRMYHarmony Biosciences 3.13Buy$53.6367.11% UpsideNVAXNovavax 2.29Hold$17.00150.18% UpsideCurrent Analyst Ratings BreakdownLatest CPRX, HRMY, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.006/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.005/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.004/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/8/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.37$2.47 per share8.77$6.10 per share3.55HRMYHarmony Biosciences$714.73M2.58$2.94 per share10.91$11.56 per share2.78NVAXNovavax$682.16M1.61N/AN/A($3.89) per share-1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.5713.7810.160.8736.91%42.45%36.59%8/6/2025 (Estimated)HRMYHarmony Biosciences$145.49M$2.6212.2510.320.4820.53%24.32%15.92%8/5/2025 (Estimated)NVAXNovavax-$187.50M$2.652.5684.940.0638.14%-115.51%29.99%8/14/2025 (Estimated)Latest CPRX, HRMY, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.145.96HRMYHarmony Biosciences0.223.673.63NVAXNovavaxN/A2.062.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%HRMYHarmony Biosciences86.23%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%HRMYHarmony Biosciences23.60%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableHRMYHarmony Biosciences20057.42 million43.87 millionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableCPRX, HRMY, and NVAX HeadlinesRecent News About These CompaniesNovavax, Inc. (NVAX) Latest Stock News & Headlines - Yahoo FinanceJuly 3 at 5:27 PM | finance.yahoo.comRFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine ApprovalJuly 3 at 1:41 PM | benzinga.comRFK Jr.‘s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientistsJuly 3 at 6:16 AM | fortune.comModerna’s Shares Gain in Premarket as New Flu Shot Shows Promising ResultsJuly 1 at 2:12 PM | tokenist.comTIs Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?July 1 at 10:01 AM | zacks.comNovavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeJune 27, 2025 | zacks.comVaccines and antibodies up for debate at CDC advisory panel meetingJune 26, 2025 | reuters.comNovavax Approval Process a Potential ‘Harbinger’ of Threat to FDA Integrity: Former RegulatorsJune 26, 2025 | biospace.comBNovavax, Inc. (NVAX) latest stock news and headlines - Yahoo FinanceJune 25, 2025 | uk.finance.yahoo.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowJune 24, 2025 | zacks.comNovavax Shareholders Approve Key Proposals at Annual MeetingJune 24, 2025 | tipranks.comNotable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focusJune 22, 2025 | msn.comNovavax Faces Challenges Amid Stock DeclineJune 21, 2025 | tipranks.comNovavax (NVAX) Ascends While Market Falls: Some Facts to NoteJune 20, 2025 | zacks.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowJune 19, 2025 | zacks.comNovavax slips as Citi launches with Sell rating on pipeline concernsJune 17, 2025 | seekingalpha.comNovavax slips as Citi launches with Sell rating on pipeline concernsJune 17, 2025 | msn.comNovavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?June 17, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Earns Sell Rating from Analysts at CitigroupJune 17, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 17, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)June 14, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPRX, HRMY, and NVAX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$21.64 +0.19 (+0.89%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$21.35 -0.29 (-1.34%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Harmony Biosciences NASDAQ:HRMY$32.09 -0.02 (-0.06%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$32.18 +0.09 (+0.28%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Novavax NASDAQ:NVAX$6.80 +0.04 (+0.52%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$6.82 +0.03 (+0.44%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
